GlassScriptPhysician profile
Njideka E Udochi
NPI 1952580821
$11,854.13
in general payments reported to CMS, 2019-2025
58 companies · $807 in 2025
The $807 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,006 · 2020: $1,615 · 2021: $1,881 · 2022: $1,928 · 2023: $2,081 · 2024: $1,536 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,212 · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,211.83 |
| Education | $212.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,459.65 | 2020-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $1,248.45 | 2019-2025 | Biktarvy |
| Astellas Pharma US INC | $778.31 | 2019-2025 | Veozah |
| Abbvie INC. | $745.74 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $660.63 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $630.44 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Allergan, INC. | $463.11 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $395.77 | 2019-2025 | Gardasil 9, Pneumovax 23, M-M-R II |
| Janssen Biotech, INC. | $359.93 | 2019-2023 | Symtuza |
| Theratechnologies INC. | $324.42 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $316.88 | 2020-2025 | Airsupra, Breztri, Xigduo |
| Indivior INC. | $280.26 | 2019-2025 | Sublocade |
| Corcept Therapeutics | $227.62 | 2022-2023 | Korlym |
| Orexo US, INC. | $211.69 | 2019-2022 | |
| Glaxosmithkline, LLC. | $188.84 | 2019-2020 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Njideka Udochi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.